$116 Million is the total value of Savitr Capital, LLC's 62 reported holdings in Q1 2013. The portfolio turnover from Q4 2012 to Q1 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2013 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-04-29
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATLAS PIPELINE PARTNERS LP | 5 | Q2 2014 | 14.5% |
| SUMMIT MIDSTREAM PARTNERS LP | 5 | Q2 2014 | 12.7% |
| USA COMPRESSION PARTNERS LP | 5 | Q2 2014 | 10.0% |
| ACCESS MIDSTREAM PARTNERS L | 5 | Q2 2014 | 6.3% |
| DCP MIDSTREAM PARTNERS LP | 5 | Q2 2014 | 5.7% |
| MARKWEST ENERGY PARTNERS L P | 5 | Q2 2014 | 3.7% |
| USA TECHNOLOGIES INC | 5 | Q2 2014 | 2.2% |
| NOVAGOLD RES INC | 5 | Q2 2014 | 1.0% |
| MIDWAY GOLD CORP | 5 | Q2 2014 | 0.1% |
| TARGA RESOURCES PARTNERS LP | 4 | Q1 2014 | 6.4% |
View Savitr Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Savitr Capital, LLC | January 28, 2020 | 2,770,535 | 5.4% |
| HERON THERAPEUTICS, INC. /DE/ | January 28, 2016 | 1,791,604 | 6.1% |
| AP PHARMA INC /DE/ | February 15, 2013 | 38,095,238 | 11.8% |
| Molecular Insight Pharmaceuticals, Inc. | April 20, 2011 | 288,074 | 1.1% |
View Savitr Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2020-01-28 |
| SC 13G/A | 2016-01-28 |
| SC 13G/A | 2016-01-28 |
| 5 | 2015-02-12 |
| 13F-HR | 2014-08-12 |
| 13F-HR | 2014-05-15 |
| 13F-HR/A | 2014-02-18 |
| 13F-HR | 2014-02-13 |
| 13F-HR | 2013-11-12 |
| 13F-HR | 2013-08-14 |
View Savitr Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.